Neuropathic Pain
📧 Sign up to get email alerts when something new happens for Neuropathic Pain.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2022-06-09Clinical Trial Update: BotulInum Toxin Type A for Peripheral Neuropathic Pain in subjEcts With Carpal Tunnel Syndrome [Phase 2]
Phase 2 clinical trial update for Botulinum Toxin Type A targeting peripheral neuropathic pain in carpal tunnel syndrome with neurogenic inf…
-
EMA withdrawal · 2022-04-26EMA Withdrawn: Pregabalin Mylan Pharma (pregabalin) — Mylan S.A.S.
EMA withdrawal notice for pregabalin marketed by Mylan S.A.S., affecting anxiety disorders, neuralgia, and epilepsy indications.
-
CLINICAL_TRIALS trial_result · 2022-02-23Clinical Trial Update: Treatment of Neuropathic Pain in Leprosy [Phase 3]
Phase 3 trial update for treatment of neuropathic pain in leprosy.
-
CLINICAL_TRIALS trial_result · 2022-02-08Clinical Trial Update: Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain [Phase 2]
Phase 2 trial assessing the efficacy of capsaicin patch (Qutenza) for cancer-related neuropathic pain has completed.
-
CLINICAL_TRIALS trial_result · 2021-11-15Clinical Trial Update: Evaluation of Initiation Time on the Efficacy of Gabapentin in Treating Neuropathic Pain in SCI [Phase 4]
Phase 4 trial evaluating how initiation time affects gabapentin efficacy for neuropathic pain in spinal cord injury was completed with resul…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2021-10-15FDA Approved: GABAPENTIN — Supplemental Application (QUALLENT PHARMACEUTICALS HEALTH LLC)
FDA approved a supplemental application for gabapentin from Quallent Pharmaceuticals Health LLC, resulting in the approval of their generic …
-
FDA approval · 2021-10-01FDA Approved: GABAPENTIN — Original Application (XLCare Pharmaceuticals, Inc.)
FDA approved the original ANDA for gabapentin from XLCare Pharmaceuticals, enabling a generic version of the anticonvulsant.
-
CLINICAL_TRIALS trial_result · 2021-09-30Clinical Trial Update: Omnitram Safety and Efficacy in the Treatment of Diabetic Neuropathy [Phase 2]
Phase 2 trial update on Omnitram for diabetic neuropathy, reporting safety and efficacy results.
-
FDA approval · 2021-09-29FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Supplemental Application (AiPing Pharmaceutical, Inc.)
FDA approved a supplemental application for Amitriptyline Hydrochloride, a generic product submitted by AiPing Pharmaceutical, Inc., under t…
-
CLINICAL_TRIALS trial_result · 2021-06-18Clinical Trial Update: Improving Functions in Veterans With Post-traumatic Peripheral Neuropathic Pain [NA]
A completed clinical trial investigating improvements in function for veterans with post-traumatic peripheral neuropathic pain; results post…
-
FDA approval · 2021-05-19FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Original Application (Unichem Pharmaceuticals (USA), Inc.)
FDA approved Amitriptyline hydrochloride as an original-application generic from Unichem Pharmaceuticals (USA), Inc. (ANDA 214548).
-
CLINICAL_TRIALS trial_result · 2021-04-28Clinical Trial Update: Localized Neuropathic Pain: Topical Treatment Versus Systemic Treatment [Phase 4]
Phase 4 trial comparing topical versus systemic treatment for localized neuropathic pain was terminated.
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: Oral LAT8881 in Neuropathic Pain [Phase 2]
Phase 2 clinical trial update for oral LAT8881 in neuropathic pain conditions has been completed with results posted.
-
CLINICAL_TRIALS trial_result · 2021-03-23Clinical Trial Update: Clinical Phenotyping and Genotyping of HIV-Associated Sensory Neuropathy: The HIV-POGO Study
Clinical trial update describing phenotyping and genotyping of HIV-associated sensory neuropathy (HIV-POGO) completing enrollment with resul…
-
FDA approval · 2021-02-19FDA Approved: AMITRIPTYLINE HYDROCHLORIDE — Original Application (Lifestar Pharma LLC)
FDA-approved Amitriptyline hydrochloride as a generic product via Original Application by Lifestar Pharma LLC.
-
CLINICAL_TRIALS trial_result · 2021-01-28Clinical Trial Update: Methadone in Neuropathic Pain [Phase 4]
A Phase 4 trial evaluating methadone for chronic neuropathic pain was terminated.
-
CLINICAL_TRIALS trial_result · 2021-01-22Clinical Trial Update: A Study to Assess the Efficacy, Safety and Tolerability of Pregabalin in Patients With Symptoms of Neuropathic Pain [Phase 3]
Phase 3 trial assessing pregabalin for neuropathic pain has completed.
-
CLINICAL_TRIALS trial_result · 2021-01-12Clinical Trial Update: Ziconotide as First-Line IDT [Phase 4]
A Phase 4 trial evaluating ziconotide as first-line intrathecal therapy for neuropathic pain has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-19Clinical Trial Update: Spinal Cord Stimulation (SCS) for Neuropathic Pain of Back or Lower Extremity [NA]
A terminated clinical trial update for spinal cord stimulation in neuropathic pain affecting the back or lower extremities, with results pos…
-
FDA approval · 2020-12-16FDA Approved: NEURONTIN — Supplemental Application (Parke-Davis Div of Pfizer Inc)
The FDA approved a supplemental application for Neurontin (gabapentin) submitted by Parke-Davis Division of Pfizer Inc, indicating a change …
-
CLINICAL_TRIALS trial_result · 2020-12-04Clinical Trial Update: Ambulatory Infusions of Lidocaine and Ketamine for Management of Chronic Pain [Phase 4]
A Phase 4 trial evaluating ambulatory infusions of lidocaine and ketamine for chronic neuropathic pain and fibromyalgia has been completed.
-
CLINICAL_TRIALS trial_result · 2020-11-18Clinical Trial Update: Donepezil Compared to Placebo in Patients With Chronic Neuropathic Pain [Phase 4]
Phase 4 trial updating Donepezil vs placebo in chronic neuropathic pain; study TERMINATED with results posted.
-
FDA approval · 2020-09-29FDA Approved: GABAPENTIN — Supplemental Application (ScieGen Pharmaceuticals, Inc.)
FDA approved a supplemental application for Gabapentin from ScieGen Pharmaceuticals, Inc.
-
FDA approval · 2020-03-23FDA Approved: PREGABALIN — Original Application (Creekwood Pharmaceuticals LLC)
FDA approves Creekwood Pharmaceuticals LLC's Original Application (ANDA) for pregabalin, enabling a generic version of the drug. This action…
-
CLINICAL_TRIALS trial_result · 2019-11-06Clinical Trial Update: Follow-up of Post-spinal Implantable Neurostimulator PRECISION®
A completed clinical trial update for the PRECISION post-spinal implantable neurostimulator, with results posted in 2019, studying chronic r…